Search

An abstract of the article "Sonographic findings on first trimester CRL growth by using maternal variables (BMI)," by E. Ancuta and colleagues is presented.

An abstract of the article "The accuracy of nuchal fold, cerebellum and cistern magna estimation using ultrasonography at 14-16 weeks of gestation," by E. Ancuta and colleagues is presented.

An abstract of the article "Use of third trimester assessment for fetal biometry and cervical length for the prediction of cesarean delivery in nulliparas," by E. Acunta and colleagues is presented.

An abstract of the article "Assessment of abdominal circumference among 29-33 gestational weeks adding a three hour oral glucose tolerance test can predict macrosomia," by E. Ancuta and colleagues is presented.

An abstract of the article "Sonographic detection of association between intrauterine device position and bleeding pattern," by C. Ancuta and colleagues is presented.

An abstract of the article "Quantifying extension and prediction of cytoreduction in ovarian cancer using subjective evaluation of ultrasound findings," by E. Ancuta and colleagues is presented.

An abstract of the conference paper "The evaluation of concomitant chemo-radiotherapy response in advanced cervical carcinoma by using transvaginal ultrasonography," by G. Ancuta and colleagues is presented.

An abstract of the conference paper "Prognostic value of transvaginal ultrasound for the evaluation of volume of tumour in cervical carcinoma," by G. Ancuta and colleagues is presented.

An abstract of the conference paper "Predictive value of Doppler assessment for the fetal umbilical and cerebral hemodynamic response in anemic pregnancies," by M. E. Ancuta, C. Ancuta and C. Iordache is presented.

An abstract of the conference paper "The possible use of transvaginal color Doppler ultrasound in predicting the response to concurrent chemo-radiotherapy in advanced cervical cancer," by E. Ancuta, and colleagues is presented.

An abstract of the conference paper "The possible use of color Doppler flow in planning treatment in stage I and II cervical carcinoma" by E. Ancuta and colleagues is presented.

Objective: CXCL10 (also known as interferon-γ-inducible 10-kd protein [IP-10]) is a chemokine that potentially plays a role in the immunopathogenesis of rheumatoid arthritis (RA). We undertook this phase II study to evaluate the efficacy and safety of MDX-1100, a fully human, anti-CXCL10 (anti-IP-10) monoclonal antibody, in RA patients whose disease responded inadequately to methotrexate (MTX)., Methods: Patients with active RA receiving stable doses of MTX (10-25 mg weekly) were randomized to receive intravenous doses of 10 mg/kg MDX-1100 (n = 35) or placebo (n = 35) every other week. The primary end point was the proportion of patients meeting the American College of Rheumatology 20% improvement criteria (achieving an ACR20 response) on day 85, and patients were followed up for safety to day 141., Results: The ACR20 response rate was significantly higher among MDX-1100-treated patients than among placebo-treated patients (54% versus 17%; P = 0.0024). Statistically significant differences in the ACR20 response rate between treatments were observed starting on day 43 (P < 0.05). The ACR50 and ACR70 response rates on day 85 did not differ between the groups. Overall, 51.4% of MDX-1100-treated patients and 30.3% of placebo-treated patients experienced at least 1 adverse event (AE). No study drug-related serious AEs were reported., Conclusion: MDX-1100 was well tolerated and demonstrated clinical efficacy in RA patients whose disease responded inadequately to MTX. This is the first study to demonstrate clinical efficacy of a chemokine inhibitor in RA and supports the notion of a potential role of IP-10 in the immunopathogenesis of RA., (Copyright © 2012 by the American College of Rheumatology.)